WuXi AppTec Co-CEO Stresses Need for True Resilience Beyond Redundancy in Biopharma Innovation

In a recent Fierce Biotech interview, WuXi AppTec co-CEO Dr. Steve Yang discussed how the biopharma sector can build resilience as scientific challenges grow.

Yang said resilience is not just about having duplicate sites or supply-chain backups; it also requires systems that keep innovation moving forward despite changing science or market conditions, without losing speed or quality.

He highlighted that rising scientific complexity is the biggest source of fragility and argued that integrated infrastructure and execution capabilities are essential for companies to keep pace with advances such as PROTAC therapeutics, whose first approved drug appeared earlier this year.

Yang concluded that the industry’s ability to persist through uncertainty demonstrates its underlying resilience, and that future innovation will depend on building adaptable, robust platforms.